

[View this email in your browser](#)

Vitiligo International
Patient Organizations
Committee



NEWSLETTER

We're thrilled to announce an upcoming event in Brussels to celebrate World Vitiligo Day. This event holds great significance as it brings together Vitiligo patient representatives for a series of workshops, advocacy efforts, and collaborative projects. It's an excellent opportunity to foster education, empowerment, and support within the Vitiligo community.

Additionally, we're excited to share that our member, Deutsche Vitiligo-Bund e.V. (the German Vitiligo Foundation) recently participated in the Inviva fair held in Nuremberg from 22nd to 26th March. The booth served as an informative hub, providing valuable resources such as patient information, posters, and flyers to those interested in Vitiligo. It's a privilege to have our members engage with visitors and raise awareness about this condition.

In exciting news, we would like to highlight the latest advancement in Vitiligo treatment. Incyte has just announced that the European Commission (EC) has granted marketing authorization for Opzelura® (ruxolitinib) cream 15mg/g. This remarkable achievement marks a significant milestone in the European Union (EU), as Opzelura becomes the first and only approved treatment offering support for repigmentation in eligible patients with non-segmental Vitiligo. This chronic autoimmune disease, characterized by

depigmentation of the skin, often has a profound impact on patients' quality of life.

We're eagerly looking forward to the World Vitiligo Day event, and we hope to see you there. Stay tuned for further updates and exciting developments in the field of Vitiligo research and treatment.

Best regards,

VIPOC



With the support of VIPOC and our sponsors, we have organized an amazing event in Brussels (Belgium), during the World Vitiligo Day (WVD) celebration (25th June). The first meeting will be with the representatives of the European vitiligo organizations. The celebration will consist of 2 days for patient leaders' meetings and one day for EU advocacy.

[Read More Here](#)



Our member, the German Vitiligo Association participated in the Inviva fair from 22-26 March in Nuremberg. The booth served as an information point for people who are interested in Vitiligo. They provided patient information, posters, and flyers for interested persons.

[Find Out More](#)

[View Gallery](#)




Incyte received marketing authorization from the European Commission for Opzelura® (ruxolitinib) cream 15mg/g. It is the first approved treatment in the EU for facial involvement in non-segmental vitiligo, a chronic autoimmune disease causing skin depigmentation.

[Read More Here](#)

 [Facebook](#)

 [Website](#)

 [Instagram](#)

Copyright © 2024 Vitiligo International Patient Organization Committee, All rights reserved.
You are receiving this email because you opted in via our website or you are a member of VIPOC.

Our mailing address is:

Vitiligo International Patient Organization Committee
10 rue Lacuée
Paris 75012
France

[Add us to your address book](#)

Want to change how you receive these emails?
You can [update your preferences](#) or [unsubscribe from this list](#).



